Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial

BACKGROUND: The efficacy of crizotinib treatment for recurring EML4‐ALK‐positive non‐small cell lung cancer (NSCLC) previously treated with alectinib is unclear. Based on our preclinical findings regarding hepatocyte growth factor/mesenchymal epithelial transition (MET) pathway activation as a poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Daijiro, Isozaki, Hideko, Kozuki, Toshiyuki, Yokoyama, Toshihide, Yoshioka, Hiroshige, Bessho, Akihiro, Hosokawa, Shinobu, Takata, Ichiro, Takigawa, Nagio, Hotta, Katsuyuki, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919114/
https://www.ncbi.nlm.nih.gov/pubmed/33470536
http://dx.doi.org/10.1111/1759-7714.13825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919114/
https://www.ncbi.nlm.nih.gov/pubmed/33470536
http://dx.doi.org/10.1111/1759-7714.13825

Ejemplares similares